Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri
Francesca
F
Department of Hematology/Oncology L and A Seragnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
Testoni
Nicoletta
N
Luatti
Simona
S
Marzocchi
Giulia
G
Baldazzi
Carmen
C
Stacchini
Monica
M
Castagnetti
Fausto
F
Breccia
Massimo
M
Specchia
Giorgina
G
Pane
Fabrizio
F
Saglio
Giuseppe
G
Martinelli
Giovanni
G
Baccarani
Michele
M
Rosti
Gianantonio
G
D001549:Benzamides; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics*; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D014314:Trisomy / Q000235:genetics
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate